Shen Nan, Pan Jielu, Miao Hongyu, Zhang Haiyan, Xing Lianjun, Yu Xiao
Department of Gastroenterology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China; Institute of Digestive Diseases, Longhua Hospital, University of Traditional Chinese Medicine, Shanghai, China.
Department of Gastroenterology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Ann Palliat Med. 2021 Jul;10(7):7697-7705. doi: 10.21037/apm-21-1304.
This meta-analysis aimed to evaluate the effectiveness of fibrates in the treatment of pruritus in patients with primary biliary cholangitis (PBC), so as to guide the clinical treatment of such cases.
Searches of the PubMed, Google Scholar, and Cochrane Library databases were performed to identify randomized controlled trials (RCTs) and prospective studies published up to December 2020 that used bezafibrate and fenofibrate as treatments for pruritus in patients with PBC. Data extraction and quality evaluation of the included literature were performed. Review Manager 5.3 software was employed for statistical analysis of the data.
This meta-analysis included 7 studies, comprising 382 patients with PBC, which assessed the efficacy of bezafibrate and fenofibrate for treating pruritus. The results showed that treatment with fibrates significantly improved pruritus symptoms in patients with PBC [relative risk (RR) =6.52, 95% confidence interval (CI): 3.26-13.06, P<0.00001]. Subgroup analysis revealed that in comparison with fenofibrate (RR =5.34, 95% CI: 0.88-32.62, P=0.07), bezafibrate (RR =25.87, 95% CI: 7.93-84.42, P<0.00001) was more effective in improving pruritic symptoms in patients with PBC. Bezafibrate was also superior to fenofibrate in reducing the degree of pruritus in patients (mean difference =3.36, 95% CI: 2.62-4.09, P=0.05, I2=73%).
Fibrates can significantly improve pruritus symptoms in patients with PBC but only in a subset of patients. Further studies are needed to elucidate the pathophysiological mechanisms underlying the effect of fibrates on pruritus in PBC, and thus guide future treatment regimens.
本荟萃分析旨在评估贝特类药物治疗原发性胆汁性胆管炎(PBC)患者瘙痒的有效性,以指导此类病例的临床治疗。
检索PubMed、谷歌学术和Cochrane图书馆数据库,以识别截至2020年12月发表的使用苯扎贝特和非诺贝特治疗PBC患者瘙痒的随机对照试验(RCT)和前瞻性研究。对纳入文献进行数据提取和质量评估。使用Review Manager 5.3软件对数据进行统计分析。
本荟萃分析纳入7项研究,共382例PBC患者,评估了苯扎贝特和非诺贝特治疗瘙痒的疗效。结果显示,贝特类药物治疗可显著改善PBC患者的瘙痒症状[相对危险度(RR)=6.52,95%置信区间(CI):3.26 - 13.06,P<0.00001]。亚组分析显示,与非诺贝特相比(RR =5.34,95% CI:0.88 - 32.62,P=0.07),苯扎贝特(RR =25.87,95% CI:7.93 - 84.42,P<0.00001)在改善PBC患者瘙痒症状方面更有效。苯扎贝特在减轻患者瘙痒程度方面也优于非诺贝特(平均差值 =3.36,95% CI:2.62 - 4.09,P=0.05,I2=73%)。
贝特类药物可显著改善PBC患者的瘙痒症状,但仅对部分患者有效。需要进一步研究阐明贝特类药物对PBC患者瘙痒作用的病理生理机制,从而指导未来的治疗方案。